Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute
Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute
复制标题
DOI：
10.1007/s12185-012-1177-8
复制
发表时间：
2012-11-01
影响因子：
2.1
通讯作者：
Okamura, Takashi
中科院分区：
文献类型：
--
作者：
Nakamura, Takayuki;Oku, Eijiro;Okamura, Takashi
我们报告了在我所进行的非亲缘脐带血移植(UCBT)治疗成人T细胞白血病/淋巴瘤(ATLL)的结果。10例ATLL患者(9例急性和1例淋巴瘤)在2003年8月至2011年7月期间接受了UCBT。确诊时的中位年龄为51岁(范围37-)。从ATLL诊断到UCBT的中位时间为130天(范围为94-344天)。调理方案有6个是清髓性的，4个是降低强度的。输注有核细胞和CD34阳性细胞的中位数分别为2.52×10(7)/kg和1.04×10(5)/kg。没有植入术失败。3例发展为II级急性移植物抗宿主病，4例发展为III级。估计两年总存活率为40%(95%可信区间12-67%)。在UCBT前的6名化疗敏感患者中，有4名在UCBT后分别存活了1035、793、712和531天。在UCBT之前，四名化疗耐药患者中没有幸存者。我们的数据表明，UCBT是可行的，并为化疗敏感型ATLL患者提供长期生存。
We report the results of unrelated cord blood transplantation (UCBT) for patients with adult T-cell leukemia/lymphoma (ATLL) conducted in our single institute. Ten patients with ATLL (nine acute and one lymphoma-type) received UCBT during the period from August 2003 to July 2011. The median age at the time of diagnosis of ATLL was 51 years (range 37-64). The median period from diagnosis of ATLL to UCBT was 130 days (range 94-344). Conditioning regimens were myeloablative for six and reduced intensity for four. The median number of infused nucleated cells and CD34 positive cells were 2.52 x 10(7)/kg and 1.04 x 10(5)/kg, respectively. There was no engraftment failure. Three patients developed grade II acute graft versus host disease, and four developed grade III. The estimated 2-year overall survival was 40 % (95 % CI 12-67 %). Four of six chemosensitive patients prior to UCBT survived for 1035, 793, 712, and 531 days post-UCBT, respectively. There were no survivors among the four chemorefractory patients prior to UCBT. Our data indicates that UCBT is feasible and provides long-term survival in patients with chemosensitive ATLL.